ARMISTICE CAPITAL LLC
Q2 2022 Form 13-F
NEW YORK, NEW YORK
CIK 0001601086
· CRD 168978
· SEC-registered investment adviser
$5.7B Reported Value Total
ARMISTICE CAPITAL LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $5,499,394,945, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
1 fund
· $4.7B gross asset value
Hedge Fund: $4.7B
Source: Form ADV filed 2026-03-31
Reported value
$5.7B
Quarter over quarter
-11.7%
Holdings
175
Top-10 concentration
49.8%
Filing Structure
Reports holdings for
- Armistice Capital Master Fund Ltd. (not a 13F filer in our records) · File #028-16739 · Q4 2014 – Q1 2021
Key People
Form ADV owners & control persons
Steven Joseph Boyd
MANAGING MEMBER
Jose Yldefonso Mallonga Bautista
CHIEF COMPLIANCE OFFICER AND DEPUTY CHIEF FINANCIAL OFFICER
Anthony Joseph Cordone
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2022 13F record
Q2 2022 13F filing summary
| Period of report | June 30, 2022 |
|---|---|
| Filed | August 15, 2022 |
| Form | 13F-HR |
| Reported value | $5.7B |
| Positions | 175 |
| Change in reported value | +10.8% |
| New positions | 77 |
| Exited positions | 41 |
| Position turnover | 54.6% |
| Top-10 concentration | 49.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
333 | $8.2B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
323 | $8.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
251 | $5.6B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
357 | $8.4B |
|
Q3 2025 13F
Filed Nov 17, 2025
|
318 | $6.7B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
200 | $5.8B |
|
Q1 2025 13F
Filed May 15, 2025
|
220 | $6.7B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
227 | $7.3B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
254 | $6.3B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
250 | $7.9B |
|
Q1 2024 13F
Filed May 15, 2024
|
333 | $7.5B |
|
Q4 2023 13F
Filed Feb 13, 2024
|
290 | $7.3B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
250 | $6.5B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
218 | $6.9B |
|
Q1 2023 13F
Filed May 15, 2023
|
223 | $6.9B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
191 | $5.7B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
194 | $5.8B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
175 | $5.7B |
|
Q1 2022 13F
Filed May 16, 2022
|
139 | $5.2B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
143 | $6.1B |
28 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SPY SPDR S&P 500 ETF TR | $1.3B | 22.05% |
| 2 | IWM ISHARES TR | $567.4M | 9.9% |
| 3 | INCY INCYTE CORP | $151.9M | 2.65% |
| 4 | MRTX MIRATI THERAPEUTICS INC | $137.5M | 2.4% |
| 5 | SUPN SUPERNUS PHARMACEUTICALS INC | $136.3M | 2.38% |
| 6 | PTCT PTC THERAPEUTICS INC | $132.0M | 2.3% |
| 7 | NBIX NEUROCRINE BIOSCIENCES INC | $129.1M | 2.25% |
| 8 | TVTX TRAVERE THERAPEUTICS INC | $128.9M | 2.25% |
| 9 | REGN REGENERON PHARMACEUTICALS | $111.1M | 1.94% |
| 10 | ENTA ENANTA PHARMACEUTICALS INC | $97.8M | 1.71% |
| 11 | ORLY OREILLY AUTOMOTIVE INC | $92.0M | 1.6% |
| 12 | BMY BRISTOL-MYERS SQUIBB CO | $89.0M | 1.55% |
| 13 | VRTX VERTEX PHARMACEUTICALS INC | $87.9M | 1.53% |
| 14 | ALKS ALKERMES PLC | $87.1M | 1.52% |
| 15 | MDGL MADRIGAL PHARMACEUTICALS INC | $78.7M | 1.37% |
| 16 | DG DOLLAR GEN CORP NEW | $75.6M | 1.32% |
| 17 | MDT MEDTRONIC PLC | $71.8M | 1.25% |
| 18 | CPRX CATALYST PHARMACEUTICALS INC | $71.5M | 1.25% |
| 19 | ARGX ARGENX SE | $71.2M | 1.24% |
| 20 | DCPH DECIPHERA PHARMACEUTICALS IN | $71.0M | 1.24% |
Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.